Sage's SAGE-217 meets in Phase I/II using model of insomnia

Sage Therapeutics Inc. (NASDAQ:SAGE) reported top-line data from a double-blind, crossover, U.S. Phase I/II trial in 45 healthy volunteers showing that single doses of 30 and

Read the full 267 word article

User Sign In